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Purpose: Leber hereditary optic neuropathy (LHON) is a common cause of inherited blindness, primarily due to one of
three mitochondrial DNA (mtDNA) mutations. These mtDNA pathogenic mutations have variable clinical penetrance.
Recent linkage evidence raised the possibility that the nuclear gene optic atrophy 1 (OPA1) determines whether mtDNA
mutation carriers develop blindness. To validate these findings we studied OPA1 in three independent LHON cohorts:
sequencing the gene in discordant male sib pairs, carrying out a family-based association study of common functional
genetic variants, and carrying out a population-based association study of the same genetic variants.
Methods: We tested 3 hypothesis in three separate study groups. Study group 1: Direct sequencing of OPA1 coding
regions was performed using sequencing methodologies (Applied Biosystems, Foster City, CA). Chromatograms were
compared with the GenBank reference sequence NM_015560.1. Splice-site prediction was performed using GeneSplicer.
Study group 2: Genotyping for rs166850 and rs10451941 was performed by restriction fragment length polymorphism
(RFLP) analysis with specific primers for both genotypes, using The restriction enzymes RsaI and FspBI to discriminate
genotypes. Study group 3: Genotyping for rs166850 and rs10451941 was performed by primer extension of allele-specific
extensions products by matrix-associated laser desorption/ionisation time-of-flight (MALDI-TOF, Seqeunom, San Diego,
CA) mass spectrometry. Allele and genotype frequencies were compared using Pearson’s chi-square test. Multiple logistic
regression was performed to look for interactions between the variables. All analyses were performed using SPSS software
version 17.0 (SPSS Inc.).
Results: In all three groups we were unable to find an association between OPA1 genetic variation and visual failure in
LHON mtDNA mutation carriers.
Conclusions: Our findings suggest that genetic variation in OPA1 is unlikely to make a major contribution to the risk of
blindness in LHON mutation carriers.
Leber  hereditary  optic  neuropathy  (LHON,  OMIM
535000)  is  a  common  cause  of  inherited  blindness  that
typically  presents  with  bilateral,  painless,  subacute  visual
failure in young adult males [1]. Affected individuals develop
focal degeneration of the optic nerve and present clinically
with impaired color vision (dyschromatopsia), a dense visual
field defect (central or cecocentral scotoma), and abnormal
visual electrophysiology due to primary retinal ganglion cell
loss [1]. The diagnosis is usually confirmed by molecular
genetic analysis for one of three common mitochondrial DNA
(mtDNA)  mutations,  which  all  affect  genes  coding  for
complex I subunits of the respiratory chain: m.3460G>A, m.
11778G>A,  and  m14484T>C.  However,  not  all  patients
harboring  a  pathogenic  LHON  mtDNA  mutation  develop
visual failure [2]. Segregation analysis of LHON pedigrees
implicates a two-locus model, with the mtDNA mutation as
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one locus, together with a modulating chromosomal locus
[3]. Attempts to identify a nuclear modifying gene by both
genetic  mapping  and  functional  genomics  have  been
inconclusive [4-6]. Recently, a region of chromosome 3 was
identified as important in determining the risk of visual loss
in LHON [7]. Although this work led to a report associating
the presenilin associated, rhomboid-like (PARL) gene with the
LHON  phenotype,  the  same  linkage  region  harbors  optic
atrophy 1 (OPA1), a gene critical to mitochondrial function.
This  raises  the  possibility  that  the  PARL  association  was
mediated through linkage disequilibrium with the OPA1 gene.
OPA1  is  a  nuclear  gene  coding  for  a  mitochondrial
protein critical for mtDNA maintenance, effective oxidative
phosphorylation,  and  maintenance  of  the  mitochondrial
network [8-10]. Mutations in OPA1 are a principle cause of
autosomal  dominant  optic  atrophy  (DOA)  [11-13].  Like
LHON, DOA has a markedly variable clinical phenotype, and
both disorders share the selective loss of retinal ganglion cells
[14].  Common  genetic  variants  in  OPA1,  including
rs166850 and rs10451941, have been associated with normal
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2760tension glaucoma [15,16], a disorder which also shares the
selective loss of retinal ganglion cells with LHON and DOA
[16]. OPA1 expression also appears to be downregulated in
LHON patients [17].
With this in mind, we tested the following two hypotheses
in three independent cohorts. (1) Cosegregating pathogenic
mutations in OPA1 might explain why only approximately
40% of men harboring pathogenic LHON mtDNA mutations
develop visual failure. This was achieved by sequencing the
entire coding region of OPA1 in pairs of clinically discordant
male siblings. (2) Two functional OPA1 SNPs, rs166850 and
rs10451941,  which  were  previously  implicated  in  the
pathogenesis of optic neuropathy [16], might modulate the
phenotype in LHON pedigrees. This was achieved by carrying
out: (a) a family-based association study of a large, well-
characterized LHON pedigree, and (b) a population-based
association study of LHON mutation carriers from across
Europe. Given the established role of mtDNA haplogroups in
modulating  the  clinical  presentation  of  specific  LHON
mutations  [18],  our  analysis  incorporated  previously
determined haplogroup data.
METHODS
Subjects: Hypothesis 1 was tested in 16 discordant sib pairs.
Hypothesis 2 was tested in a large Brazilian m.11778G>A
LHON pedigree [19] (study group 2; clinically affected, n=23;
clinically  unaffected,  n=39)  as  well  as  in  an  independent
cohort of 248 LHON mtDNA mutation carriers (study group
3:  clinically  affected,  n=95;  clinically  unaffected,  n=153)
from  centers  around  Europe.  The  clinical  phenotype  was
determined by a local ophthalmologist, and all subjects were
homoplasmic for one of the three primary LHON mtDNA
mutations  (study  group  1  -  clinically  affected  mt.
11778G>A=16 and clinically unaffected mt.11778G>A=16;
study  group  2  -  clinically  affected  mt.11778G>A=23  and
clinically  unaffected  mt.11778G>A=39;  study  group  3  -
clinically affected, mt.3460G>A=12, mt.11778G>A=81, mt.
14484T>C=2 and clinically unaffected, mt.3460G>A=26, mt.
11778G>A=126, mt.14484 T>C=1). This was confirmed by
direct  sequencing  of  the  relevant  mitochondrial  NADH
dehydrogenase  genes  (MTND-1,  −4  and  −6)  or  by  PCR-
restriction  fragment-length  polymorphism  analysis,  as
previously described [20]. Unaffected carriers were classified
and included only if they had remained asymptomatic until
over 30 years of age.
Molecular studies:
Study  group  1—Direct  sequencing  of  OPA1  coding
regions  was  performed  using  sequencing  methodologies
(Applied  Biosystems,  Foster  City,  CA).  Sequence
chromatograms were directly compared with the appropriate
GenBank  reference  sequence  (NM_015560.1)  using
SeqScape software (v2.1, Applied Biosystems). Splice-site
prediction was performed using GeneSplicer [21].
Study  group  2—Genotyping  for  rs166850  and
rs10451941  was  performed  by  restriction  fragment-length
polymorphism  analysis  with  specific  primers  for  both
genotypes (sense, 5′-CCC TTT TAG TTT TTA CGA TGA
AGA-3′; antisense, 5′-TTG CTT AAG ACA TTA CTT GGA
ACA-3′).  The  restriction  enzymes  RsaI  and  FspBI
(Fermentas,  York,  UK)  discriminated  the  respective
genotypes.
Study  group  3—Genotyping  for  rs166850  and
rs10451941 was performed by primer extension of allele-
specific  extension  products  by  matrix-associated  laser
desorption/ionization  time-of-flight  mass  spectrometry
(MALDI-TOF; Seqeunom, San Diego, CA). Genotypes were
confirmed in 10% of random samples, by direct sequencing
using a genetic analyzer (ABI3100; Applied Biosystems).
Statistical analysis: Allele and genotype frequencies were
compared using Pearson’s chi-square test. Multiple logistic
regression was performed to look for interactions between the
variables. All analyses were performed using the Statistical
Package for Social Sciences software (version 17.0; SPSS
Inc., Middlesex, UK).
RESULTS
OPA1 sequencing in study group 1: Sequencing of OPA1
coding  regions  in  LHON  sib  pairs  did  not  identify  any
previously reported pathogenic mutations in LHON sib pairs
[22]. Seven previously reported synonymous polymorphisms
  e   identified    (rs7624750,    rs60201300,    rs34307082, r e w
rs10451941,   rs9831900,        rs9851685,    and    rs10937595)     
  [23];   however,  none  segregated   with  the  disease  either
individually  (Table 1)  or  in  different  combinations,  and
no  variant  was  predicted  to  disrupt  exon  splicing.  The 
frequency  of  these  variants  was  not  significantly different
from that of the background population.
rs166850 and rs10451941 genotyping:
Study  group  2—There  was  no  association  between
either rs166850 or rs10451941 and visual failure in the large
Brazilian  m.11778G>A  pedigree  for  both  alleles,
independently (Pearson’s p=0.669 and p=1.00, respectively;
Table 2) or for the genotypes (Pearson’s p=0.491 and p=0.966,
respectively; Table 2).
Study  group  3—There  was  no  association  between
rs166850 or rs10451941 and visual failure in the European
LHON mutation carriers when comparing alleles (Pearson’s
p=0.115  and  p=1.00,  respectively;  Table  3)  or  genotypes
(Pearson’s p=0.161 and p=0.959, respectively; Table 3). As
previous  studies  have  shown,  the  rs166850:  rs10451941
CT:TT  genotype  is  associated  with  increased  risk  of
developing  normal  tension  glaucoma  (NTG),  which,
comparable  to  LHON,  preferentially  affects  the  retinal
ganglion  cell  [16].  We  therefore  performed  analyses  of
rs166850:  rs10451941  complex  genotypes  versus  LHON
(Table 4). Tests of association did not reveal any link between
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pathogenic LHON mutation.
Relationship  to  mitochondrial  DNA  haplogroup  J:  The
clinical penetrance of the LHON mutations m.11778G>A and
m.14484T>C  is  strongly  associated  with  mitochondrial
haplogroup J [18]. With this is mind, we compared OPA1
rs166850 and rs10451941 genotypes in both LHON J and non-
J haplogroups by logistic regression analysis, which controls
for age, gender, and the specific LHON mtDNA mutation.
This failed to identify an interacting association between the
background  mitochondrial  haplogroup  J,  the  OPA1
rs166850 and rs10451941 genotypes, and the incidence of
visual failure in LHON patients (p values: rs166850 genotype,
p=0.464; for rs10451941 genotype, p=0.801; for combined
complex genotypes, p=0.616). There was also no significant
association identified in non-J haplogroups.
DISCUSSION
This study was designed to test the hypothesis that genetic
variation in OPA1 is the major factor determining why only
the minority of LHON mtDNA mutation carriers develop
visual failure. Our study of three independent cohorts found
no  evidence  to  support  this  hypothesis.  Whole-gene
sequencing  in  discordant  sib  pairs  did  not  identify  a
pathogenic OPA1 variant. The polymorphic variants that were
identified  were  synonymous  and  poorly  conserved  in  the
population  (mean  population  heterozygosity;
rs35801538=0.031,  rs9851685=0.495,  and
rs35540805=0.027,  dbSNP,  [23]),  and  not  previously
associated  with  visual  failure.  Unlike  glaucoma,  we  were
unable  to  identify  an  association  between  the  rs166850:
rs10451941 genotype and the risk of visual impairment in a
large, well characterized Brazilian LHON pedigree (study
group  2).  Being  maternally  related,  all  of  the  Brazilian
TABLE 1. ALLELIC FREQUENCY COMPARISON OF SNPS IDENTIFIED IN STUDY GROUP 1, DISCORDANT LHON SIB-PAIRS
(WHERE A=AFFECTED, U=UNAFFECTED SIBLING AND P IS UNCORRECTED PROBABILITY BY FISHERS EXACT TEST).
SNP A (n=32) U (n=32) p
rs7624750 7 5 0.750
rs60201300 21 19 0.079
rs34307082 8 8 1.000
rs10451941 21 19 0.079
rs9831900 21 19 0.079
rs9851685 7 5 0.750
rs10937595 21 19 0.079
           The table shows no significant association to OPA1 variants and disease.
TABLE 2. ANALYSIS OF OPA1: RS166850 AND RS10451941 FREQUENCIES IN STUDY GROUP 2, THE BRAZILIAN LHON PEDIGREE
(WHERE, A=AFFECTED; U=UNAFFECTED, AND P IN UNCORRECTED PROBABILITY BY PEARSON’S CHI-SQUARE TEST).
SNP Status C T p CC CT TT p
rs166850 A 43 3 0.669 20 3 0 0.491
U 75 3 36 3 0
rs10451941 A 25 21 1.000 896 0.966
U 42 36 14 14 11
           The table shows no significant association to either OPA1 alleles or genotypes in study group 2.
TABLE 3. ANALYSIS OF OPA1: RS166850 AND RS10451941 FREQUENCIES IN STUDY GROUP 3, EUROPEAN LHON
MUTATION CARRIERS (WHERE, A=AFFECTED; U=UNAFFECTED, AND P IN UNCORRECTED PROBABILITY BY PEARSON’S CHI-
SQUARE TEST).
SNP Status C T p CC CT TT p
rs166850 A 156 34 0.115 64 28 3 0.161
U 268 38 116 36 1
rs10451941 A 99 91 1.000 24 51 20 0.959
U 159 147 37 85 31
           The table shows no significant association to common OPA1 variants and disease in study group 3.
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2762mutation carriers harbored the same LHON mtDNA mutation
(m.11778G>A)  and  belonged  to  the  same  mtDNA
background haplogroup (J) [19]. Given the well established
relationship between visual loss and both the specific mtDNA
mutation and the background mtDNA haplogroup [18], we
studied a third group and determined the relationship between
the clinical phenotype and both rs166850 and rs10451941 in
isolation; a multivariate analysis accounted for the specific
primary mtDNA LHON mutation and the mtDNA haplogroup
(study group 3). Once again we found no evidence of an
association between common functional genetic variants of
OPA1 and visual failure in LHON mtDNA mutation carriers.
Having tested the hypothesis in several different ways
and in different cohorts, we conclude that it is unlikely that
genetic variation in OPA1 makes a major contribution to the
risk of blindness in LHON mutation carriers. Although we
cannot  exclude  a  more  subtle  genetic  effect,  such  as  an
influence on the age at onset of the visual failure or chance of
recovery, either directly or through an interaction with other
genes, a much larger study is required to address this issue.
This may not be technically possible, given the relative rarity
of LHON mtDNA mutation carriers in the general population.
Based on the results presented here, it seems more likely that
other genetic and environmental factors explain the variable
penetrance of this mtDNA disorder [24].
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